← Back to Search

Bromodomain and Extraterminal Domain (BET) Inhibitor

Apabetalone for Coronavirus Disease

Phase 2 & 3
Waitlist Available
Research Sponsored by Resverlogix Corp
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Aged ≥18 years
Subjects showing bilateral pulmonary infiltrates on chest imaging
Timeline
Screening 3 weeks
Treatment Varies
Follow Up study day 28
Awards & highlights

Study Summary

This study is evaluating whether a drug may help treat individuals with a certain type of pneumonia.

Eligible Conditions
  • Coronavirus Disease

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~study day 28
This trial's timeline: 3 weeks for screening, Varies for treatment, and study day 28 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The primary endpoint of the study is the change in WHO Ordinal Scale for Clinical Improvement at Day 14
Secondary outcome measures
Biomarkers of inflammation Interleukin-6
Biomarkers of inflammation Interleukin-8
Biomarkers of inflammation Tumor Necrosis Factor alpha
+2 more

Side effects data

From 2021 Phase 3 trial • 2425 Patients • NCT02586155
8%
Worsening diabetes mellitus
6%
Hypertension
6%
Angina
5%
ALT increase
5%
Angina unstable
5%
Urinary tract infection
4%
Nasopharyngitis
4%
Influenza
4%
Diarrhoea
3%
Angina pectoris
3%
Anemia
3%
Non-cardiac chest pain
3%
Myalgia
3%
Acute myocardial infarction
2%
Upper respiratory tract infection
2%
Pneumonia
2%
Back pain
2%
Bronchitis
2%
Hepatobiliary
2%
Cardiac failure
2%
Nausea
1%
Arthralgia
1%
Atrial fibrillation
1%
Peripheral arterial occlusive disease
1%
Musculoskeletal chest pain
1%
Pain in extremity
1%
Myocardial infarction
1%
Abdominal pain
1%
Coronary artery disease
1%
Cardiac failure acute
1%
Acute kidney injury
100%
80%
60%
40%
20%
0%
Study treatment Arm
High-Intensity Statin Therapy+RVX000222
High-Intensity Statin Therapy+Placebo

Trial Design

2Treatment groups
Experimental Treatment
Group I: Standard of Care plus apabetaloneExperimental Treatment2 Interventions
All subjects will receive SOC during their hospital admission. This will include daily vital signs, WHO Ordinal Scale assessment and adverse events. On Days 3, 5, 7 and 11, hematology, chemistry, oropharyngeal or nasopharyngeal swabs for Covid-19 viral levels and biomarkers samples the same as at the screening visit will be taken if the patient remains in hospital. For the apabetalone cohort, treatment will be administered BID with meals.
Group II: Standard of CareExperimental Treatment1 Intervention
All subjects will receive SOC during their hospital admission. This will include daily vital signs, WHO Ordinal Scale assessment and adverse events. On Days 3, 5, 7 and 11, hematology, chemistry, oropharyngeal or nasopharyngeal swabs for Covid-19 viral levels and biomarkers samples the same as at the screening visit will be taken if the patient remains in hospital.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Apabetalone
2015
Completed Phase 3
~2440

Find a Location

Who is running the clinical trial?

Resverlogix CorpLead Sponsor
11 Previous Clinical Trials
3,452 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
An Open-Label Study of Apabetalone in Covid Infection
2022. "An Open-Label Study of Apabetalone in Covid Infection". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04894266.
~0 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top